QUANTUM LEAP HEALTH CARECOLLABORATIVE

As filed

Subsection

03

NTEE code

P20

Classification

1000

Street

580 CALIFORNIA STREET

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

• ISPY 2.2 - I-SPY 2.2 USES A 'SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL' (SMART) DESIGN - THAT IS BOTH SMART AND ADAPTIVE. THE TRIAL CONSISTS OF UP TO THREE BLOCKS OF TREATMENT. THE FIRST, BLOCK A, INCLUDES NOVEL TARGETED THERAPIES, WITHOUT STANDARD CHEMOTHERAPY. IF A PATIENT ACHIEVES A COMPLETE RESPONSE AFTER BLOCK A, THEY CAN AVOID TOXIC CHEMOTHERAPY AND GO DIRECTLY TO SURGERY. IF THEY HAVE RESIDUAL CANCER, OR THE TREATMENT IS FOUND TO HAVE LITTLE EFFECT HALFWAY THROUGH THE COURSE OF TREATMENT, THEY ARE RECOMMENDED TO PROCEED TO TREATMENT IN BLOCK B. IN BLOCK B, PATIENTS ARE ASSIGNED A TREATMENT REGIMEN MOST LIKELY TO WORK FOR THEIR SUBTYPE, OFTEN COMBINED WITH CHEMOTHERAPY SINCE THE RISK OF TOXICITY IS MORE ACCEPTABLE IN PATIENTS WITH MORE RESISTANT CANCER. (CONTINUED ON SCHEDULE O)IF BLOCK B TREATMENT IS EFFECTIVE, THE PATIENT CAN SKIP ADDITIONAL CHEMOTHERAPY AND GO TO SURGERY. ONLY IF THEY STILL HAVE TUMOR LEFT AFTER BLOCK B, WILL THE PATIENTT GET RESCUE THERAPY WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE A CHEMOTHERAPY REGIMEN THAT HAS BEEN AROUND FOR DECADES. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 36.9%

  Expenses $31,082,090 · Revenue $28,146,883

• DCIS - THE RE-EVALUATING CONDITIONS FOR ACTIVE SURVEILLANCE SUITABILITY AS TREATMENT: DUCTAL CARCINOMA IN SITU (RECAST DCIS) PLATFORM TRIAL IS A LANDMARK PHASE 2 TRIAL THAT IS CHANGING THE LENS THROUGH WHICH WE TREAT DCIS. THE STUDY IS AIMED AT PREVENTING THE PROGRESSION OF DCIS TO BREAST CANCER AND IS EVALUATING THREE INVESTIGATIONAL ENDOCRINE THERAPY ARMS.WITH THE OBJECTIVE TO AVOID OVER-TREATMENT OF LOW-RISK DCIS PATIENTS, THIS NEW TRIAL OFFERS DCIS PATIENTS ENDOCRINE THERAPY WITH THE INTENT TO IDENTIFY PATIENTS WHO ARE RESPONSIVE TO NON-INVASIVE TREATMENT AND HAVE THE OPTION TO OMIT SURGERY AND BE MONITORED VIA LONG-TERM ACTIVE SURVEILLANCE. (CONTINUED ON SCHEDULE O)A KEY ELEMENT IN REDUCING OVER TREATMENT OF DCIS IS IDENTIFYING BIOMARKERS THAT REFLECT THE RISK OF PROGRESSION SO THAT THOSE WITH LOW-RISK LESIONS ARE SPARED SURGERY. RECAST DCIS FEATURES THE ASSESSMENT OF MRI IMAGING AND MOLECULAR-BASED BIOMARKER ANALYSES IN ADDITION TO EVALUATING NEW INVESTIGATIONAL AGENTS IN THIS SETTING. IF PATIENTS AND THEIR PHYSICIANS AGREE, THEY MAY BE ABLE TO STAY ON ENDOCRINE THERAPY FOR UP TO THREE YEARS. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 7.2%

  Expenses $2,337,901 · Revenue $3,517,864

• PHASE1B - PRE I-SPY IS AN OPEN-LABEL PHASE 1B PLATFORM STUDY DESIGNED TO EVALUATE SINGLE AGENTS OR COMBINATIONS IN A METASTATIC TREATMENT SETTING THAT MAY BE RELEVANT FOR BREAST CANCER PATIENTS WITH THE OVERALL GOAL OF MOVING PROMISING DRUG REGIMENS INTO THE I-SPY 2.2 TRIAL AND/OR OTHER ONCOLOGY-BASED TRIALS IN A TIMELY MANNER. THE PRIMARY OBJECTIVES OF THIS PLATFORM TRIAL ARE TO DETERMINE THE SAFETY AND TOLERABILITY OF NEW AGENTS/REGIMES IN PATIENTS WITH CERTAIN ADVANCED SOLID TUMORS AND BREAST CANCER WHILE OBTAINING PRELIMINARY EFFICACY DATA OF THE NEW AGENTS/REGIMES. THE STUDY WAS DEVELOPED TO HELP INVESTIGATORS AND INDUSTRY PARTNERS MEET THE SAFETY QUALIFICATIONS NECESSARY FOR PARTICIPATION IN I-SPY 2.2 (CONTINUED ON SCHEDULE O) TRIAL AND/OR OTHER PHASE II/III STUDIES. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 7.00%

  Expenses $271,185 · Revenue $1,877,278

• OTHER PROGRAMS INCLUDE BREAST CANCER TRIALS (BCT) MATCH, COVID-19 TRIALS, I-SPY 2.0, ENDOCRINCE OPTIMIZATION PROJECT (EOP) TRIALS, AND ONE SOURCE AI.

  Expenses $21,638,115 · Revenue $8,948,949

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2024

  Revenue

  $45,532,346

  Expenses

  $62,568,780

  Contributions

  $878,580

  Grants paid

  $0

• 2023

  Revenue

  $45,147,899

  Expenses

  $47,759,442

  Contributions

  $1,389,552

  Grants paid

  $0

• 2022

  Revenue

  $47,253,845

  Expenses

  $47,240,395

  Contributions

  $18,937,275

  Grants paid

  $0

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $56,142,324

  Expenses

  $43,755,562

  Assets (EOY)

  $64,443,428

• 2021 · 990

  Revenue

  $56,142,324

  Expenses

  $43,755,562

  Assets (EOY)

  $64,443,428

• 2020 · 990

  Revenue

  $40,966,658

  Expenses

  $23,555,958

  Assets (EOY)

  $46,710,842

• 2019 · 990

  Revenue

  $15,089,173

  Expenses

  $14,639,065

  Assets (EOY)

  $16,681,889

• 2018 · 990

  Revenue

  $12,445,452

  Expenses

  $11,720,572

  Assets (EOY)

  $13,623,504

• 2017 · 990

  Revenue

  $12,489,295

  Expenses

  $10,601,758

  Assets (EOY)

  $11,141,939

• 2016 · 990

  Revenue

  $11,440,896

  Expenses

  $8,277,669

  Assets (EOY)

  $8,443,360

• 2015 · 990

  Revenue

  $9,066,877

  Expenses

  $13,699,037

  Assets (EOY)

  $6,493,314

• 2014 · 990

  Revenue

  $2,241,657

  Expenses

  $10,301,480

  Assets (EOY)

  $5,173,469

• 2011 · 990

  Revenue

  — not reported

  Expenses

  $1,684,896

  Assets (EOY)

  $690,689

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.

Grants received

• THE ALBERTSONS COMPANIES FOUNDATION

  $230,000

  2023 · OTHER

• THE ALBERTSONS COMPANIES FOUNDATION

  $200,000

  2024 · CANCER PREVENTION AND TREATMENT

• MORGAN STANLEY GLOBAL IMPACT FUNDING TRUST INC

  $37,500

  2023 · UNRESTRICTED GENERAL SUPPORT

• MORGAN STANLEY GLOBAL IMPACT FUNDING TRUST INC

  $20,000

  2024 · UNRESTRICTED GENERAL SUPPORT

• MORGAN STANLEY GLOBAL IMPACT FUNDING TRUST INC

  $17,000

  2022 · UNRESTRICTED GENERAL SUPPORT

• DONOR ADVISED CHARITABLE GIVING

  $12,000

  2024 · HUMAN SERVICES

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $11,250

  2024 · For grant recipient's exempt purposes

• THE MIAMI FOUNDATION INC

  $10,000

  2025 · PROGRAM SUPPORT

• PLUMPJACK FOUNDATION

  $10,000

  2024 · PAYMENTS TO OTHER ORGANIZATIONS

• AMERICAN ONLINE GIVING FOUNDATION INC

  $9,998

  2022 · GENERAL SUPPORT

The 10 largest by cash amount. The API serves every itemized grant.

Other IRS files